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Abstract 
Patients with schizophrenia show whole brain and cortical gray matter (GM) volume 
reductions which are progressive early in their illness. Microglia, the resident immune 
cells in the CNS, phagocytose neurons and synapses. Some post mortem and in 
vivo studies in schizophrenia show evidence for elevated microglial activation 
compared to matched controls. However, it is currently unclear how these results 
relate to changes in cortical structure. 
Methods 
Fourteen patients with schizophrenia and 14 ultra high risk for psychosis (UHR) 
subjects alongside two groups of age and genotype matched healthy controls 
received [11C]PBR28 PET scans to index TSPO expression, a marker of microglial 
activation and a 3T MRI scan. We investigated the relationship between the volume 
changes of cortical regions and microglial activation in cortical GM (as indexed by 
[11C]PBR28 distribution volume ratio (DVR).  
Results 
The total cortical GM volume was significantly lower in SCZ than the controls [mean 
(SD)/cm3: SCZ=448.83 (39.2) and controls=499.6 (59.2) (p=0.02) but not in UHR 
(mean (SD)=503.06 (57.9) and controls=524.46 (45.3) p=0.3).  Regression model 
fitted the total cortical GM DVR values with the cortical regional volumes in SCZ 
(r=0.81; p<0.001) and in UHR (r=0.63; p=0.02). We found a significant negative 
correlation between the TSPO signal and total cortical GM volume in SCZ with the 
highest absolute correlation coefficient in the right superior-parietal cortex (r=-0.72; 
p=0.006).  
Conclusions 
These findings suggest that microglial activity is related to the altered cortical volume 
seen in schizophrenia. Longitudinal investigations are required to determine whether 
microglial activation leads to cortical gray matter loss. 
 
Key words: Schizophrenia, microglia, brain volume, PET, gray matter, psychosis
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INTRODUCTION 
 
Patients with schizophrenia have been consistently shown to have reduced whole 
brain and cortical gray matter volume relative to matched controls (Ellison-Wright et 
al., 2008; Haijma et al., 2013). Moreover, longitudinal brain morphometric studies 
show there are progressive reductions in gray and white matter volume in 
schizophrenia (Andreasen et al., 2011; Kahn and Sommer, 2015; van Haren et al., 
2008). Similarly people at ultra high risk for psychosis (UHR), have reduced cortical 
and gray matter volumes (Dazzan et al., 2012), and demonstrate evidence for 
progressive loss during the transition to psychosis (Cannon et al., 2015; Pantelis et 
al., 2003; Sun et al., 2009; Ziermans et al., 2012). In contrast, elevations in white 
matter volume have been observed in schizophrenia, although less consistently 
(Walterfang et al., 2008; Witthaus et al., 2008). It is interesting to note that the 
change over time in cortical volume has been found to be related to change in 
symptoms and a transition from at risk symptoms to first episode psychosis 
(Borgwardt et al., 2007b). Baseline volumes have also been shown to act as a 
predictive marker for transition (Borgwardt et al., 2007a). 
 
Though the exact pathophysiology of the brain morphometric changes in 
schizophrenia is not clear, immune dysregulation has been suggested as an 
underlying mechanism (Bergink et al., 2014; Fillman et al., 2016; Kirkpatrick and 
Miller, 2013; Laskaris et al., 2016).  Supporting this, experimental animal studies of 
maternal immune activation show altered fetal brain development and behavioural 
and brain histopathological changes in offspring (Smith et al., 2007). Elevated levels 
of pro-inflammatory cytokines have been associated with the reductions in gray 
matter volume in patients with schizophrenia (Meisenzahl EM, 2001), and loss of 
gray matter in frontal cortex was associated with greater levels of pro-inflammatory 
cytokines in people at risk of psychosis who transitioned to psychosis (Cannon et al., 
2015). Microglia, the brain’s resident immune cells, have a major role in synaptic 
pruning and phagocytosis within the central nervous system (Kreutzberg, 1996; 
Paolicelli et al., 2011). They are both activated by pro-inflammatory cytokines and 
release them (Hanisch, 2002; Kreutzberg, 1996). A recent rodent model based on 
immune loci identified in the largest genome-wide association study in schizophrenia 
4 
 
to date showed that these genetic alterations lead to altered microglial pruning of 
synapses (Sekar et al., 2016). Moreover, post mortem studies show elevated 
markers of inflammation (Fillman et al., 2013; Foster et al., 2006; van Kesteren et al., 
2017; Volk et al., 2015) and elevated microglial cell density (with a hypertrophic 
morphology) in the brains of schizophrenia patients compared with healthy controls 
(Bayer et al., 1999), particularly in the frontal and temporal lobes (Radewicz, 2000; 
van Kesteren et al., 2017).   A recent systematic review and meta-analysis of post 
mortem brain studies in schizophrenia found significant increase in the density of 
microglia in patients compared to healthy controls (van Kesteren et al., 2017) but 
another review did not find any consistent difference in microglia markers in 
schizophrenia (Trépanier et al., 2016). Microglial activation might thus disrupt 
synaptic pruning to result in the gray matter volume loss seen in schizophrenia 
(Laskaris et al., 2016). Supporting this, a recent post-mortem study has shown that 
greater inflammatory brain markers are associated with smaller brain volumes in 
schizophrenia (Zhang   et al., 2016).  
  
Microglia express the 18kDa translocator specific protein (TSPO), a mitochondrial 
membrane protein, when they become activated, and can be indexed by PET tracers 
such as [11C]PBR28 that selectively bind to it (Brown et al., 2007; Owen et al., 2014; 
Owen et al., 2011). Thus [11C]PBR28 is an in vivo biomarker of microglial activation 
(Abourbeh et al., 2012; Dickens et al., 2014; Karlstetter et al., 2014; Lartey et al., 
2014; Mattner et al., 2013; Rupprecht et al., 2010). We have recently reported 
increased [11C]PBR28 distribution volume ratio (DVR) in cortical gray matter in 
medicated patients with schizophrenia as well as UHR subjects when compared to 
healthy controls (Bloomfield et al., 2016b) using positron emission tomography (PET) 
imaging. This finding is consistent with some (Doorduin et al., 2009b; van Berckel et 
al., 2008), but not all  PET studies, which either have reported no change (Collste et 
al., 2017; Coughlin et al., 2016; Hafizi et al., 2017; Holmes et al., 2016; Kenk et al., 
2015; van der Doef et al., 2016) or a decrease in volume of distribution (VT) (Collste 
et al., 2017) in patients with psychosis or schizophrenia compared to healthy 
controls, suggesting there may be clinical or methodological differences between 
studies (Turkheimer et al., 2015b).  
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Microglial activation has been long associated with diaschisis: e.g. the 
phenomenon whereby local brain changes lead to functional alterations in 
areas distant from but connected to the initial area of damage (von Monakow 
in 1906)(Carrera and Tononi, 2014). As a result of diaschisis, secondary 
changes in the thalamus, substantia nigra pars reticulata, hippocampus and 
spinal cord have been well reported after focal ischemic or excitotoxic lesions 
of the cortex and/or striatum, and these are associated with inflammatory 
changes characterized by activation of microglia and astrocytes (Block et al., 
2005). Notably, the facial nerve lesion model that Georg Kreutzberg introduced 
as the stereotypical preparation to study microglial response to injury in tissue 
with an intact blood-brain barrier, demonstrates microglial activation as a 
result of secondary injury (Blinzinger and Kreutzberg, 1968). PET imaging 
using [11C]-(R)-PK11195 has reported secondary thalamic and hippocampal 
increases in [11C]-(R)-PK11195 after stroke, traumatic brain injury, 
neurodegeneration and aging both in animal models and humans (Arlicot et 
al., 2010; Cagnin et al., 2001; Holmberg et al., 2009; Myers et al., 1991; Ouchi et 
al., 2005; Pappata et al., 2000; Ramlackhansingh et al., 2011; Schuitemaker et 
al., 2012a). The specificity of these findings has been elegantly demonstrated 
by Radlinska et al. (Radlinska et al., 2009) who showed [11C]-(R)-PK11195 
increases in the spinal tract of patients with anterograde infarct as determined 
by diffusion tensor imaging. Notably, secondary microglia activation does not 
seem limited to anterograde and retrograde projections. Banati et al. (Banati et 
al., 2001) reported a trans-synaptic increase in [11C]-(R)-PK11195 binding in the 
thalamus of a male patient with limb denervation. Subsequently, Gerhard et 
al.(Gerhard et al., 2005) reported [11C]-(R)-PK11195 increases in the ipsilateral 
thalamic nuclei of six stroke patients. A meta-analysis of post-mortem studies 
of microglia in schizophrenia indicate that alterations are seen across a 
number of brain regions (van Kesteren et al., 2017), and there is no clear 
evidence for regional specificity of microglial or TSPO changes, albeit 
relatively few regions have been investigated and studies are probably 
underpowered to detect regional differences (Bloomfield et al., 2016b; Collste 
et al., 2017; Coughlin et al., 2016; Doorduin et al., 2009b; Hafizi et al., 2017; 
Holmes et al., 2016; Kenk et al., 2015; van Berckel et al., 2008; van der Doef et 
al., 2016; van Kesteren et al., 2017). Our prior [11C]PBR28 TSPO study found an 
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alteration in cortical gray matter throughout the brains of patients with 
schizophrenia (Bloomfield et al., 2016b). Given the above, we predicted that 
alterations in microglial in schizophrenia would be linked to the generalized 
structural cortical reductions seen in schizophrenia (Ellison-Wright and 
Bullmore, 2010). In view of this, we modeled [11C]PBR28 TSPO alterations in 
schizophrenia with a multivariate statistical model to capture the cross-
correlation between  alterations in the TSPO measure and structural changes 
across the brain. As this involved a large number of regions, we used an 
elastic net approach because this controls for the multiple potential cross-
correlations. To our knowledge, to-date, no studies that have investigated the 
link between microglial activation with brain volumetric changes in vivo in 
schizophrenia and subjects at risk of psychosis. Our a priori hypothesis was 
that microglial activity would inversely correlate with the total gray matter 
volume in schizophrenia patients and UHR subjects (increased [11C]PBR28 in 
patients with more gray matter volume deficits).  
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METHODS 
 
Subjects 
Fourteen subjects meeting UHR criteria, as assessed on the comprehensive 
assessment of the at risk mental state (CAARMS) (Yung et al., 2005), were recruited 
from a London mental health clinic (Mean age ± SD: 24.3 ± 5.40; (M:F=7:7)). 
Fourteen subjects with schizophrenia (Mean age ± SD: 47.0 ± 9.31; (M:F=12:2)) 
were recruited from London mental health centres (South London and Maudsley 
NHS Foundation Trust). A pool of 22 healthy control subjects recruited through 
newspaper and poster adverts were used to provide two groups (n=14 and n=14) of 
age and genotype matched subjects for the two experimental cohorts (Table 1). The 
patients and controls were from the same study that was recently 
published(Bloomfield et al., 2016b). The study was approved by the local research 
ethics committee and was conducted in accordance with the Declaration of Helsinki. 
After complete description of the study to the subjects, written informed consent was 
obtained. 
All subjects met the following inclusion criteria: 
1. Aged 18+; 
2. No significant physical or psychiatric health contraindications on assessment 
and medical examination by a trained physician. 
 
Subjects were then screened based on the following exclusion criteria; 
1. Exposure to any somatic medications, including anti-inflammatory 
medications, in the last 1 month. 
2. History of substance abuse/dependence as determined by the Structured 
Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 
IV (DSM-IV) (SCID) (Spitzer et al., 1992). 
3. Benzodiazepine use, whether prescribed or not (Rao and Butterworth, 
1997). One subject was excluded due to a positive urine drug screening 
result for benzodiazepines on the scan day. 
4. History of head injury resulting in unconsciousness, or any physical 
medical condition associated with inflammation. 
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5. At the time of screening, subjects were tested for TSPO genotype and 
subjects with a low affinity genotype were excluded as the PET radiotracer 
shows negligible specific binding(Owen et al., 2011). 
6. In UHR and control subjects: antipsychotic medication exposure. 
7. Significant prior exposure to radiation 
8. Pregnancy or breast feeding. 
 
Healthy control subjects with a personal history of a psychiatric disorder or a first 
degree relative with schizophrenia or a psychotic illness were excluded. 
 
PET Imaging 
All subjects then received a bolus injection of [11C]PBR28 (mean Mbq activity ±SD: 
325.31 ± 27.03) followed by a 90-minute emission scan using a Siemens Biograph™ 
TruePoint™ PET-CT scanner (Siemens Medical Systems, Germany). A computer 
tomography (CT) scan was also acquired for attenuation and scatter correction. 
Images were reconstructed using filtered back projection and binned into 26 frames 
of increasing time length (durations: 8 x 15 s, 3 x 1 min, 5 x 2 min, 5 x 5 min, 5 x 10 
min). During the PET acquisition, arterial blood data were sampled via the radial 
artery using a combined automatic-manual approach. A continuous (one sample per 
second) sampling system (ABSS Allogg, Mariefred, Sweden) measured whole blood 
activity for the first 15 minutes of each scan. Discrete blood samples manually 
withdrawn at 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 minutes, were centrifuged 
to determine the plasma over blood activity ratio and filtered using HPLC to calculate 
the plasma fraction of authentic tracer free of metabolites (Tonietto et al., 2015; 
Tonietto et al., 2016). For further details please refer to original study and its 
supplementary material (Bloomfield et al., 2016b). 
 
MRI imaging 
Each subject underwent a MRI brain scan acquired with a 3T magnetic resonance 
imaging (MRI) scanner (Trio, Siemens Medical Systems, Germany). T1-weighted 
images were acquired with a 32-channel head coil (except for one subject where a 
12-channel coil was used due to operator error) on a Siemens Tim Trio, 3-T MRI 
scanner (Siemens Healthcare, Erlangen, Germany). A magnetization-prepared rapid 
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gradient echo (MPRAGE) sequence produced a 3D structural image with a 1 mm3 
voxel size constructed from 160 slices (thickness 1mm) [time repetition (TR) = 2300 
ms, time echo (TE) = 2.98 ms, flip angle of 9°, time to inversion (TI) = 900 ms, matrix 
coil mode = 24 channel Auto (Triple), FoV read = 256 mm, FoV phase = 93.8%]. 
 
Image analysis  
 
MRI Cortical volume measures 
Cortical reconstruction and volumetric segmentation on T1 weighted images were 
performed with the Freesurfer version 5.3 (http://surfer.nmr.mgh.harvard.edu) (Dale 
et al., 1999). The procedure involved intensity normalization, automated 
topology corrections and automatic segmentations of cortical and subcortical 
regions. The PET, but not MR, data for these subjects have been reported in full 
(Bloomfield et al., 2016b). The cortex was segmented into 68 regions (34 in each 
hemisphere) based on the Desikan-Killiany Atlas (Desikan et al., 2006), and the 
volume of each cortical region was calculated using the standard Freesurfer 
pipeline (Dale et al., 1999). The volumes of the cortical regions were used as input 
features to the regression model (see below). Widespread gray matter reductions 
are consistently reported in schizophrenia in total cortical gray matter, frontal cortex 
and temporal cortex and therefore these brain areas were selected as regions of 
interests (ROIs)(Andreasen et al., 2011; Haijma et al., 2013; Honea et al., 2005). In 
addition, we found increased [11C]PBR28 relative binding in total cortical gray matter, 
frontal cortex and temporal cortex in patients with schizophrenia and individuals at 
risk of psychosis (Bloomfield et al., 2016b). The frontal cortex included bilateral 
caudal middle frontal cortex, lateral orbitofrontal cortex, medial orbitofrontal cortex, 
pars opercularis, pars orbitalis, pars triangularis, rostral middle frontal cortex, 
superior frontal cortex, and frontal pole; the temporal cortex included bilateral banks 
of superior temporal sulcus, entorhinal cortex, fusiform cortex, inferior temporal 
cortex, middle temporal cortex, parahippocampal cortex, superior temporal cortex, 
temporal pole, and transverse temporal cortex. 
 
PET imaging 
All PET images were corrected for head movement using non-attenuation corrected 
images, as they include greater scalp signal, which improves re-alignment compared 
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to attenuation-corrected images (Montgomery et al., 2006). Frames were realigned 
to a single ‘reference’ space identified by the individual T1 MRI scan. The 
transformation parameters were then applied to the corresponding attenuation-
corrected PET frames, creating a movement-corrected dynamic image for analysis. 
Structural MRI images were used for gray/white matter segmentation and region of 
interest (ROI) definition. A neuroanatomical atlas (Tziortzi et al., 2011) was co-
registered on each subject’s MRI scan first and then on the correspondent PET 
image using a combination of Statistical Parametric Mapping8 
(http://www.fil.ion.ucl.ac.uk/spm) and FSL (http://www.fsl.fmrib.ox.ac.uk/fsl) functions, 
implemented in MIAKATTM (http://www.miakat.org). Regional time-activity curves 
(TACs) were obtained by sampling the image with the coregistered atlas. The 
primary region of interest was total cortical gray matter. Secondary regions of interest 
were temporal and frontal lobe gray matter regions from the atlas (Radewicz, 2000).  
 
Quantification of [11C]PBR28 tissue distribution was performed using the two tissue 
compartmental model accounting for endothelial vascular TSPO binding (2TCM-1K) 
(Rizzo et al., 2014; Veronese et al., 2017), as this has been shown to have improved 
performance compared with the two tissue compartmental model not accounting for 
endothelial binding (2TCM) (Rizzo et al., 2014). To account for variability of inter-
subject blood binding, typical of TSPO targeting tracers (Albrecht et al., 2016; 
Lockhart et al., 2003; Turkheimer et al., 2015b), regional distribution volume 
estimates were normalized for whole brain activity in agreement with previous 
studies (Loggia et al., 2015; Zürcher et al., 2015). 
 
Our primary outcome measure therefore was the adjusted distribution volume ratio 
(DVR) calculated using an multiple analysis of covariance (MANCOVA) covarying 
for confounding factors that affect TSPO tracer binding (Turkheimer et al., 2015b). 
This approach produces estimated marginal means, in which the ROIs of interest are 
the dependent variables and genotype, age and whole brain signal are used as 
covariates. There are data to suggest that cortical microglial activation, hence TSPO 
binding, is elevated with aging (Schuitemaker et al., 2012b), which is also evident in 
our data (see (Bloomfield et al., 2016b), Supplemental Table 2). TSPO genotype 
was included as a co-variate in correlation analysis as there is evidence that a single 
nucleotide polymorphism affecting the TSPO gene significantly affects binding of the 
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tracer (Owen et al., 2011). For this reason, we performed correlation analysis using 
age, genotype and whole brain signal as covariates. We also performed analysis 
using volume of distribution (VT) as secondary outcome measure. Volume of 
distribution (VT) is defined as the ratio of the radioligand concentration in target 
region to that in plasma at equilibrium (Innis et al., 2007).  
 
 
Statistical analysis 
Data, other than for gender and genotype, were shown to have a normal distribution 
following a Shapiro-Wilk test (Shapiro, 1965). Hence parametric tests were 
implemented for all but gender and affinity analyses, where a Mann-Whitney U test 
was used. Demographic data and tracer activity data were analysed using 
independent-samples t-tests.  
 
Within each cohort, multiple analysis of covariance (MANCOVA) was used to 
determine whether there was an effect of the group on [11C]PBR28 adjusted DVR in 
the total cortical gray matter, frontal lobe, and temporal lobe, as well as on the total 
cortical gray matter volume and regional volumes within frontal and temporal lobes. 
These regions were chosen as regions of interest based on previous microglial 
activation studies (Doorduin et al., 2009a; van Berckel et al., 2008). For all statistical 
comparisons alpha was set at a 0.05 threshold (two-tailed) for significance. The 
results were reported in our recently published study (Bloomfield et al., 2016b) 
and presented in the supplementary table 1.  
 
For cortical volume analysis, within each cohort, the volume of each cortical region 
was compared between the two groups with the t-test. A false discovery rate (FDR) 
at 0.05 was used to control the false positives across the multiple comparisons 
among the brain regions (Benjamini and Hochberg, 1995; Nichols and Hayasaka, 
2003) . 
 
The main objective was to investigate the relationship between cortical microglial 
activation and the cortical gray matter volume decreases in patients. We therefore 
investigated the relationship between the differences in the volume of cortical 
regions and microglial activation in cortical gray matter (as indexed by [11C]PBR28 
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DVR). We performed a regression analysis of the total cortical gray matter 
[11C]PBR28 DVR value (dependent variable) against all the regional cortical gray 
matter volumes (independent variables) as described above. As the number of 
investigated regions was larger than the number of observations, we implemented a 
regulation of the parameters with the elastic net regularized general linear models 
(Zou and Hastie). Elastic net is a statistical regularization and variable selection 
method that prevents overfitting of the regression  (Zou and Hastie). Because the 
parameter optimization is dependent on an internal cross-validation procedure, the 
performance of the regression may vary depending on sample stratification. To 
control the variability ‘r’, we performed 1000 iterations of the regression and used the 
mean correlative coefficients for the final regression model, and report the 
distribution of r and –logp values of the 1000 iterations (Carroll et al., 2009). The r 
values were between 0.7 and 1 and the –logp values were well beyond 2, indicating 
good fitting at a significance level of 0.01 or lower across all the iterations. The 
resulting regressed DVR and the DVR measured in our study was evaluated with 
Pearson’s correlation analysis to investigate the accuracy of the regression. To 
further investigate the localized relationship between the DVR and cortical region 
volumes, we also performed exploratory analyses using the same regression 
analysis within the DVR and regional volumes of the frontal cortex, as well as 
the DVR and regional volumes of the temporal cortex. The primary region of 
interest was total cortical gray matter. For the total cortical gray matter DVR, 
regression included all 68 regions of the cortex (i.e to identify which of the 68 cortical 
regional variables were most associated with cortical gray matter DVR). In the 
exploratory analyses, for the frontal and temporal lobe DVR, we included 18 
regions within frontal and temporal cortex as secondary regions of interests, 
respectively. The regression analysis was performed with MATLAB (version R2013a, 
The Mathworks Inc., Natick, Massachusetts) with glmnet package (Qian et al., 2013).  
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RESULTS 
 
Cortical Gray Matter Volume Analysis (SCZ vs Controls) 
 
The total cortical gray matter volume was significantly lower in SCZ than the healthy 
controls (p=0.02) (Table 1).  Temporal cortical gray matter volume was also lower in 
Scz than controls but not frontal cortical gray matter volume (Table 1). Whole brain 
analysis with false discovery rate  set at 0.05, revealed significantly lower gray 
matter volumes in schizophrenia patients compared to healthy control subjects in the 
following three regions; left cuneus, right superior parietal cortex and right transverse 
temporal cortex (Table 1).  
 
Cortical Gray Matter Volume Analysis (UHR vs Controls) 
 
The total cortical, frontal or temporal gray matter volume was not different between 
the UHR and the controls (Table 1). No significant volume difference was observed 
in the whole brain analysis at FDR 0.05.  
 
Table 1 (to be inserted) 
 
Relationship between [11C]PBR28 DVR and brain volume in the SCZ  
 
Total cortical gray matter [11C]PBR28 DVR and brain volume   
 
In the schizophrenia patients the volumes of cortical regions were significantly 
related to total cortical gray matter [11C]PBR28 DVR (r=-0.83; p<0.001) in the 
regression model. The top weighted regions were the right superior parietal cortex, 
left middle frontal cortex, left isthmus of the cingulate cortex, left temporal pole, and 
right lateral orbital frontal cortex. All these regions contributed negatively to the DVR 
values, indicating smaller volumes in these regions are related to greater total 
cortical [11C]PBR28 DVR. The region with the highest absolute correlation coefficient 
was the right superior-parietal cortex, and its volume was negatively correlated with 
the total cortical gray matter DVR (r=-0.70; p=0.008; Figure 1a). The regression 
found no significant relationship between total cortical gray matter DVR and 
cortical gray matter volumes in the matched healthy controls.  
14 
 
 
The distributions of the r and p values for the 1000 iterations indicate that the 
regression model using cortical gray matter volumes provided a good fit of the total 
cortical gray matter DVR as shown in Figure 1b. The lowest r value was 0.70, when 
the model used only one region volume (the right superior-parietal cortex) to fit the 
total cortical gray matter DVR. 
 
Figure 1 (to be inserted) 
Regional cortical gray matter [11C]PBR28 DVR and brain volume  
 
In this exploratory analyses, we also found that in the schizophrenia patients the 
gray matter DVR in the temporal cortex was significantly related to the volumes of 
left temporal pole, right superior temporal cortex, left and right entorhinal cortex, and 
right transverse temporal cortex (r=0.94; p<0.0001; Figure 4). The region with the 
highest absolute regression coefficient was the left temporal pole, which showed a 
negative correlation with the temporal cortical GM DVR (r=-0.72; p=0.005; Figure 5). 
The distributions of the r and p values for the 1000 iterations are shown in Figure 6. 
In contrast, there was no significant fit between the DVR values of the frontal lobe 
with the frontal volumes. 
 
Figure 2 (to be inserted) 
 
Relationship between [11C]PBR28 DVR and brain volume in the UHR 
 
For the UHR group, the regression model found a significant fit between the total 
cortical gray matter DVR with the cortical region volumes (r=0.63; p=0.02). The 
regression model also fitted the DVR of the temporal lobe with its volumes (r=0.76; 
p=0.002). None of the regions used in the regression correlated with the DVR of the 
total cortical or temporal gray matter, indicating an additive effect from multiple 
regions. The regression model did not fit the DVR values of the frontal lobe with the 
corresponding volumes. 
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Finally, direct regional correlations between [11C]PBR28 DVR and MRI volume for 
cortical GM, frontal lobe, and temporal lobe in both schizophrenia patients and UHR 
subjects matched to their respective control groups were not significant (p>0.05). 
 
 
Relationship between [11C]PBR28 VT and brain volume 
 
In the schizophrenia patients, the regression model found a significant fit between 
the total cortical gray matter VT with the cortical region volumes (r=0.98; p<0.001) 
and temporal lobe (r=-0.88; p<0.001). However, none of the regions used in the 
regression correlated with the VT of the total cortical or temporal gray matter, which 
may indicate additive effect that otherwise were not predictive for VT individually. 
There was no gray matter volume ROI that was statistically significantly correlated 
with VT (Supplement Fig 1), though there was a trend towards a negative correlation 
between VT and gray matter volume in the temporal lobe (left transverse temporal 
volume r=-0.51; p=0.07; Supplement Fig  2). There was no significant fit between the 
frontal region VT values with the frontal volumes.  
 
In the UHR subjects, the regression model found a significant fit between the total 
cortical gray matter VT with the cortical region volumes (r=0.90; p<0.001), temporal 
lobe (r=0.68; p<0.001) and frontal lobe (r=0.80; p<0.001). The region with the 
highest absolute correlation coefficient was the right pars orbitalis cortex, and its 
volume was positively correlated with the total cortical gray matter VT (r=0.76; 
p=0.002; Supplement Fig 3). For temporal gray matter VT, the highest absolute 
correlation coefficient was the left transverse temporal area (r=0.61; p=0.02; 
Supplement Fig 4) and for frontal lobe was right pars orbitalis cortex (r=0.71; 
p=0.004; Supplement Fig 5). 
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DISCUSSION 
 
In this experiment, we investigated the relationship between cortical volumes and 
TSPO signal from [11C]PBR28 PET scans in patients with schizophrenia, UHR 
subjects and respective matched control groups. We demonstrated that patients with 
schizophrenia exhibit a negative relationship between total cortical gray matter 
[11C]PBR-28 DVR and cortical gray matter volumes, and this was also seen for 
temporal cortex DVR and temporal cortical volumes. The lack of relationship in the 
healthy control subjects may suggest that relationship between total cortical gray 
matter [11C]PBR-28 DVR and cortical gray matter volumes is disorder specific. It is 
also possible lack of relationship in the healthy control subjects is due to the limited 
[11C]-PBR-28 DVR range in this cohort.  In the UHR group, although the regression 
model fitted the DVR values of total cortical and temporal gray matter with the 
respective cortical region volumes, no individual regions showed any significant 
correlation.  
 
To our knowledge this study is the first to investigate the relationship between 
microglia and cortical volumes in schizophrenia and UHR cohorts using multimodal 
imaging. Our findings are consistent with the hypothesis that microglial activation 
leads to GM volume reduction, but, as they are associations, a direct causal 
relationship cannot be inferred. Although the regression model indicated there is a 
relationship between DVR and gray matter volumes in the UHR group, there was no 
single region that showed a correlation between [11C]PBR28 DVR and cortical 
volumes. This difference with the schizophrenia results may reflect illness 
progression as UHR subjects are earlier in the development of disorder and many 
UHR subjects do not go on to develop schizophrenia. It would be interesting to follow 
up the UHR cohorts to examine the brain GM volume change and [11C]PBR28 signal 
during the course of the prodromal period to determine if there is a change with 
illness progression.  
 
A similar significant inverse correlation between [11C]PBR28 binding and gray matter 
volume is also observed in patients with Alzheimer’s disease and mild cognitive 
impairment (Kreisl et al., 2013). Further experimental studies are required to 
17 
 
determine the biological significance of elevated microglial activity in the context of 
brain volume changes in schizophrenia (Laskaris et al., 2016).  
 
In our main [11C]PBR28 results in schizophrenia, we found increased [11C]PBR28 
DVR in patients with schizophrenia compared to healthy controls but not with 
[11C]PBR28 VT between the two groups (Bloomfield et al., 2016b). We found >30% 
level of VT variability likely due in part to a small free fraction (fp) and DVR 
normalization reduced intersubject variability and thus possibly improved the signal 
to noise in our data (Bloomfield et al., 2016b). Therefore, it is not surprising that we 
did not find any significant correlation between [11C]PBR28 VT and cortical gray 
matter or regional (temporal or frontal) volume in patients with schizophrenia. These 
differences may be accounted for by methodological issues (see discussion below). 
Notwithstanding this, the direction of both the VT and DVR correlations is consistent 
with the direction of alteration seen in schizophrenia for the respective measure in 
temporal lobe (a trend level negative correlation between [11C]PBR28 VT and in 
temporal lobe).  Finally, we observed a direct correlation between [11C]PBR28 VT and 
cortical volumes in UHR subjects. This is not what we expected and we think that 
this is likely due to noise in the data due to the fact that we did not find any 
significant differences in the gray matter volume or [11C]PBR28 VT between UHR 
subjects and healthy controls.  
 
We used distribution volume ratio (DVR) as the main outcome measure and other 
groups used distribution volume (VT) or binding potential (BP). There is currently no 
universal consensus on the optimum analytical approaches for estimation of 
microglial activation using TSPO tracers (Bloomfield et al., 2016a; Narendran and 
Frankle, 2016; Turkheimer et al., 2015b). DVR as an outcome measure has been 
validated in animals, where inflammatory stimuli increase DVRs and microglial 
markers (Converse et al., 2011; Imaizumi et al., 2007) and also in other human 
studies using [11C]PBR28 (Dimber et al., 2016; Lyoo et al., 2015) and [11C]-(R)-
PK11195 (Rissanen et al., 2014). VT is generally accepted to be the preferred 
outcome measure in the absence of a clear reference region. However, this is 
problematic for TSPO tracers for a number of reasons. Accurate VT estimation relies 
on two assumptions; first, the availability of reliable plasma input function 
measurement and second, that there are no systematic group differences in free 
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parent radiotracer plasma levels. In our cohort of Schizophrenia patients, we 
observed a very low free parent radiotracer plasma levels (~2%) and the parent 
plasma levels were significantly different across group (patients vs 
controls)(Bloomfield et al., 2016a). Therefore accurate VT determination is not 
possible and potentially unreliable (Turkheimer et al., 2015a). Another issue is the 
confounding effect of plasma protein bound to plasma tracer. Binding of TSPO 
tracers to plasma proteins has been reported(Lockhart et al., 2003). which indicates 
this could confound VT estimation as studies show patients with schizophrenia show 
elevated acute phase protein in peripheral blood (Bloomfield et al., 2016a). Thus, in 
our study, we think DVR is less likely to be affected by differences in plasma proteins 
compared to VT. However, it should be noted that interpretation of DVR increases is 
not straightforward as there is no brain region devoid of TSPO, and further work is 
warranted to confirm the relationships observed. This issue is discussed in detail 
elsewhere (Bloomfield et al., 2016a; Turkheimer et al., 2015b). 
 
Limitations 
 
Except one patient with schizophrenia, all were taking antipsychotic medications 
(Supplementary Table 2) which may be a potential confounder moderating the 
relationship between microglial activity and brain GM volume. Antipsychotic 
medications are associated with brain volume reductions in schizophrenia (Ho et al., 
2011) but volume change is related to illness progression after adjusting for 
antipsychotic effects (Van Haren et al., 2013). Some preclinical evidence suggests 
that antipsychotic medication may possess anti-inflammatory properties (Mondelli 
and Howes, 2014) by reducing microglial activity (Bian et al., 2008; Kato et al., 2008; 
Zhu F, 2014), although at higher doses they may increase microglial activity (Cotel et 
al., 2015). A recent study using [11C]-(R)-PK11195 to index TSPO availability, found 
significantly elevated [11C]-(R)-PK11195 in medicated patients (N=8)  (taking monthly 
intramuscular injections of either Risperidone or Paliperidone) compared with healthy 
controls in prefrontal, anterior cingulate and parietal cortical regions (Holmes et al., 
2016). However there were no significant differences in [11C]-(R)-PK11195 availability 
in antipsychotic-free patients (Holmes et al., 2016). Longitudinal clinical studies will 
be necessary to investigate change in brain volume and TSPO in patients with 
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schizophrenia who were medication naïve to specifically look into the effects of 
antipsychotic medication on brain volume.  
 
We did not correct for possible partial volume effects on [11C]PBR28 in this study. 
However gray matter reductions seen in schizophrenia patient would tend to 
underestimate the [11C]PBR28 DVR and thus the partial volume effect would be 
unlikely to explain the negative correlation between [11C]PBR28 DVR and GM 
observed in this study.  
 
Due to modest sample size in this study, the results have to be interpreted with 
caution. To reduce the possibility that our results were acquired by chance, we also 
performed the regression 1000 times with random folding internal cross-validations 
to select the parameters. The distribution of r values (the correlation coefficient 
between the predicted DVR with gray matter brain region volumes and the actual 
DVR) was an indicator of the possible performances of the regression model. The 
values reported in our study were near the expected values of the r.  
Future directions 
 
The causal relationship between neuroinflammation and brain volume changes will 
likely require longitudinal clinical studies that specifically look into whether TSPO 
changes predict the onset or worsening of brain volume reduction in individuals prior 
to the onset of psychosis and are antipsychotic medication naïve.  
Conclusions  
 
In schizophrenia cortical volume reduction is associated with elevated microglial 
activation using a multimodal neuroimaging approach. This relationship was also 
observed at a marginal level in UHR subjects suggesting the relationship may 
become stronger with the development of the disorder. 
 
 
Acknowledgements 
 
20 
 
Funding 
This study was funded by Medical Research Council-UK (no. MC-A656-5QD30), 
Maudsley Charity (no. 666), Brain and Behavior Research Foundation, and 
Wellcome Trust (no. 094849/Z/10/Z) grants to Dr. Howes and the National Institute 
for Health Research (NIHR) Biomedical Research Centre at South London and 
Maudsley NHS Foundation Trust and King’s College London. 
 
The views expressed are those of the author(s) and not necessarily those of the 
NHS, the NIHR or the Department of Health. 
 
Conflicts of interest 
Dr. Howes has received investigator-initiated research funding from and/or 
participated in advisory/ speaker meetings organised by Astra-Zeneca, Autifony, 
BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, 
Sunovion, Rand and Roche.  Neither Dr. Howes or his family have been employed 
by or have holdings/ a financial stake in any biomedical company. Sudhakar 
Selvaraj, Peter S Bloomfield, Cao Bo, Mattia Veronese and Federico Turkheimer 
have no conflicts of interest for this work. The authors would like to thank all the 
clinical imaging staff at Imanova for their help with this study.  
 
 
 
 
 
 
 
 
 
 
 
  
21 
 
References 
 
Abourbeh, G., Thézé, B., Maroy, R., Dubois, A., Brulon, V., Fontyn, Y., Dollé, F., Tavitian, B., Boisgard, 
R., 2012. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune 
encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator 
protein radioligand [¹⁸F]DPA-714. J Neurosci 32(17), 5728-5736. 
Albrecht, D.S., Granziera, C., Hooker, J.M., Loggia, M.L., 2016. In Vivo Imaging of Human 
Neuroinflammation. ACS Chem Neurosci 7(4), 470-483. 
Andreasen, N.C., Nopoulos, P., Magnotta, V., Pierson, R., Ziebell, S., Ho, B.C., 2011. Progressive 
brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol 
Psychiatry 70(7), 672-679. 
Arlicot, N., Petit, E., Katsifis, A., Toutain, J., Divoux, D., Bodard, S., Roussel, S., Guilloteau, D., 
Bernaudin, M., Chalon, S., 2010. Detection and quantification of remote microglial activation in rodent 
models of focal ischaemia using the TSPO radioligand CLINDE. Eur J Nucl Med Mol Imaging 37(12), 
2371-2380. 
Banati, R.B., Cagnin, A., Brooks, D.J., Gunn, R.N., Myers, R., Jones, T., Birch, R., Anand, P., 2001. 
Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. 
Neuroreport 12(16), 3439-3442. 
Bayer, T.A., Buslei, R., Havas, L., Falkai, P., 1999. Evidence for activation of microglia in patients with 
psychiatric illnesses. Neuroscience Letters 271(2), 126-128. 
Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society,   Series B (Methodological) Vol. 
57(1), 289-300. 
Bergink, V., Gibney, S.M., Drexhage, H.A., 2014. Autoimmunity, inflammation, and psychosis: a 
search for peripheral markers. Biol Psychiatry 75(4), 324-331. 
Bian, Q., Kato, T., Monji, A., Hashioka, S., Mizoguchi, Y., Horikawa, H., Kanba, S., 2008. The effect of 
atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by 
interferon-Î³. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32(1), 42-48. 
Blinzinger, K., Kreutzberg, G., 1968. Displacement of synaptic terminals from regenerating 
motoneurons by microglial cells. Z Zellforsch Mikrosk Anat 85(2), 145-157. 
Block, F., Dihné, M., Loos, M., 2005. Inflammation in areas of remote changes following focal brain 
lesion. Prog Neurobiol 75(5), 342-365. 
Bloomfield, P.S., Howes, O.D., Turkheimer, F., Selvaraj, S., Veronese, M., 2016a. Response to 
Narendran and Frankle: The Interpretation of PET Microglial Imaging in Schizophrenia. Am J 
Psychiatry 173(5), 537-538. 
Bloomfield, P.S., Selvaraj, S., Veronese, M., Rizzo, G., Bertoldo, A., Owen, D.R., Bloomfield, M.A., 
Bonoldi, I., Kalk, N., Turkheimer, F., McGuire, P., de Paola, V., Howes, O.D., 2016b. Microglial Activity 
in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging 
Study. Am J Psychiatry 173(1), 44-52. 
Borgwardt, S.J., McGuire, P.K., Aston, J., Berger, G., Dazzan, P., Gschwandtner, U., Pflüger, M., 
D'Souza, M., Radue, E.W., Riecher-Rössler, A., 2007a. Structural brain abnormalities in individuals 
with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl 51, s69-75. 
Borgwardt, S.J., Riecher-Rössler, A., Dazzan, P., Chitnis, X., Aston, J., Drewe, M., Gschwandtner, U., 
Haller, S., Pflüger, M., Rechsteiner, E., D'Souza, M., Stieglitz, R.D., Radü, E.W., McGuire, P.K., 
2007b. Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry 61(10), 
1148-1156. 
Brown, A.K., Fujita, M., Fujimura, Y., Liow, J.S., Stabin, M., Ryu, Y.H., Imaizumi, M., Hong, J., Pike, 
V.W., Innis, R.B., 2007. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a 
PET radioligand to image inflammation. J Nucl Med 48(12), 2072-2079. 
Cagnin, A., Myers, R., Gunn, R.N., Lawrence, A.D., Stevens, T., Kreutzberg, G.W., Jones, T., Banati, 
R.B., 2001. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes 
encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 124(Pt 10), 
2014-2027. 
22 
 
Cannon, T.D., Chung, Y., He, G., Sun, D., Jacobson, A., van Erp, T.G., McEwen, S., Addington, J., 
Bearden, C.E., Cadenhead, K., Cornblatt, B., Mathalon, D.H., McGlashan, T., Perkins, D., Jeffries, C., 
Seidman, L.J., Tsuang, M., Walker, E., Woods, S.W., Heinssen, R., Consortium, N.A.P.L.S., 2015. 
Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal 
neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 77(2), 147-157. 
Carrera, E., Tononi, G., 2014. Diaschisis: past, present, future. Brain 137(Pt 9), 2408-2422. 
Carroll, M.K., Cecchi, G.A., Rish, I., Garg, R., Rao, A.R., 2009. Prediction and interpretation of 
distributed neural activity with sparse models. Neuroimage 44(1), 112-122. 
Collste, K., Plavén-Sigray, P., Fatouros-Bergman, H., Victorsson, P., Schain, M., Forsberg, A., Amini, 
N., Aeinehband, S., Erhardt, S., Halldin, C., Flyckt, L., Farde, L., Cervenka, S., consortium, K.S.P.K., 
2017. Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as 
measured using PET and [(11)C]PBR28. Mol Psychiatry. 
Converse, A.K., Larsen, E.C., Engle, J.W., Barnhart, T.E., Nickles, R.J., Duncan, I.D., 2011. 11C-(R)-
PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J 
Nucl Med 52(2), 257-262. 
Cotel, M.C., Lenartowicz, E.M., Natesan, S., Modo, M.M., Cooper, J.D., Williams, S.C., Kapur, S., 
Vernon, A.C., 2015. Microglial activation in the rat brain following chronic antipsychotic treatment at 
clinically relevant doses. Eur Neuropsychopharmacol 25(11), 2098-2107. 
Coughlin, J.M., Wang, Y., Ambinder, E.B., Ward, R.E., Minn, I., Vranesic, M., Kim, P.K., Ford, C.N., 
Higgs, C., Hayes, L.N., Schretlen, D.J., Dannals, R.F., Kassiou, M., Sawa, A., Pomper, M.G., 2016. In 
vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using 
[(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry 6, e777. 
Dale, A.M., Fischl, B., Sereno, M.I., 1999. Cortical surface-based analysis. I. Segmentation and 
surface reconstruction. Neuroimage 9(2), 179-194. 
Dazzan, P., Soulsby, B., Mechelli, A., Wood, S.J., Velakoulis, D., Phillips, L.J., Yung, A.R., Chitnis, X., 
Lin, A., Murray, R.M., McGorry, P.D., McGuire, P.K., Pantelis, C., 2012. Volumetric abnormalities 
predating the onset of schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh 
risk of psychosis. Schizophr Bull 38(5), 1083-1091. 
Desikan, R.S., Ségonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., Buckner, R.L., Dale, 
A.M., Maguire, R.P., Hyman, B.T., Albert, M.S., Killiany, R.J., 2006. An automated labeling system for 
subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 
31(3), 968-980. 
Dickens, A.M., Vainio, S., Marjamäki, P., Johansson, J., Lehtiniemi, P., Rokka, J., Rinne, J., Solin, O., 
Haaparanta-Solin, M., Jones, P.A., Trigg, W., Anthony, D.C., Airas, L., 2014. Detection of microglial 
activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 
18F-GE-180. J Nucl Med 55(3), 466-472. 
Dimber, R., Guo, Q., Bishop, C., Adonis, A., Buckley, A., Kocsis, A., Owen, D., Kalk, N., Newbould, R., 
Gunn, R.N., Rabiner, E.A., Taylor, G.P., 2016. Evidence of Brain Inflammation in Patients with Human 
T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using 
11C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. J Nucl Med 57(12), 1905-1912. 
Doorduin, J., de Vries, E.F., Willemsen, A.T., de Groot, J.C., Dierckx, R.A., Klein, H.C., 2009a. 
Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50(11), 1801-1807. 
Doorduin, J., de Vries, E.F.J., Willemsen, A.T.M., de Groot, J.C., Dierckx, R.A., Klein, H.C., 2009b. 
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study. Journal of Nuclear Medicine 
50(11), 1801-1807. 
Ellison-Wright, I., Bullmore, E., 2010. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. 
Schizophr Res 117(1), 1-12. 
Ellison-Wright, I., Glahn, D.C., Laird, A.R., Thelen, S.M., Bullmore, E., 2008. The anatomy of first-
episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J 
Psychiatry 165(8), 1015-1023. 
Fillman, S.G., Cloonan, N., Catts, V.S., Miller, L.C., Wong, J., McCrossin, T., Cairns, M., Weickert, 
C.S., 2013. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of 
individuals with schizophrenia. Mol Psychiatry 18(2), 206-214. 
Fillman, S.G., Weickert, T.W., Lenroot, R.K., Catts, S.V., Bruggemann, J.M., Catts, V.S., Weickert, 
C.S., 2016. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia 
displaying poor verbal fluency and reduced Broca's area volume. Mol Psychiatry 21(8), 1090-1098. 
23 
 
Foster, R., Kandanearatchi, A., Beasley, C., Williams, B., Khan, N., Fagerhol, M.K., Everall, I.P., 2006. 
Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an 
inflammatory process? Eur J Neurosci 24(12), 3561-3566. 
Gerhard, A., Schwarz, J., Myers, R., Wise, R., Banati, R.B., 2005. Evolution of microglial activation in 
patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage 24(2), 591-595. 
Hafizi, S., Tseng, H.H., Rao, N., Selvanathan, T., Kenk, M., Bazinet, R.P., Suridjan, I., Wilson, A.A., 
Meyer, J.H., Remington, G., Houle, S., Rusjan, P.M., Mizrahi, R., 2017. Imaging Microglial Activation 
in Untreated First-Episode Psychosis: A PET Study With [(18)F]FEPPA. Am J Psychiatry 174(2), 118-
124. 
Haijma, S.V., Van Haren, N., Cahn, W., Koolschijn, P.C., Hulshoff Pol, H.E., Kahn, R.S., 2013. Brain 
volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39(5), 1129-1138. 
Hanisch, U.K., 2002. Microglia as a source and target of cytokines. Glia 40(2), 140-155. 
Ho, B.C., Andreasen, N.C., Ziebell, S., Pierson, R., Magnotta, V., 2011. Long-term antipsychotic 
treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 
68(2), 128-137. 
Holmberg, P., Liljequist, S., Wägner, A., 2009. Secondary brain injuries in thalamus and hippocampus 
after focal ischemia caused by mild, transient extradural compression of the somatosensori cortex in 
the rat. Curr Neurovasc Res 6(1), 1-11. 
Holmes, S.E., Hinz, R., Drake, R.J., Gregory, C.J., Conen, S., Matthews, J.C., Anton-Rodriguez, J.M., 
Gerhard, A., Talbot, P.S., 2016. In vivo imaging of brain microglial activity in antipsychotic-free and 
medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study. Mol Psychiatry 
21(12), 1672-1679. 
Honea, R., Crow, T.J., Passingham, D., Mackay, C.E., 2005. Regional deficits in brain volume in 
schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 162(12), 2233-
2245. 
Imaizumi, M., Kim, H.-J., Zoghbi, S.S., Briard, E., Hong, J., Musachio, J.L., Ruetzler, C., Chuang, D.-
M., Pike, V.W., Innis, R.B., Fujita, M., 2007. PET imaging with [11C]PBR28 can localize and quantify 
upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. 
Neuroscience Letters 411(3), 200-205. 
Innis, R.B., Cunningham, V.J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R.N., Holden, J., Houle, S., 
Huang, S.C., Ichise, M., Iida, H., Ito, H., Kimura, Y., Koeppe, R.A., Knudsen, G.M., Knuuti, J., 
Lammertsma, A.A., Laruelle, M., Logan, J., Maguire, R.P., Mintun, M.A., Morris, E.D., Parsey, R., 
Price, J.C., Slifstein, M., Sossi, V., Suhara, T., Votaw, J.R., Wong, D.F., Carson, R.E., 2007. 
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of cerebral 
blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and 
Metabolism 27(9), 1533-1539. 
Kahn, R.S., Sommer, I.E., 2015. The neurobiology and treatment of first-episode schizophrenia. Mol 
Psychiatry 20(1), 84-97. 
Karlstetter, M., Nothdurfter, C., Aslanidis, A., Moeller, K., Horn, F., Scholz, R., Neumann, H., Weber, 
B.H., Rupprecht, R., Langmann, T., 2014. Translocator protein (18 kDa) (TSPO) is expressed in 
reactive retinal microglia and modulates microglial inflammation and phagocytosis. J 
Neuroinflammation 11, 3. 
Kato, T., Mizoguchi, Y., Monji, A., Horikawa, H., Suzuki, S.O., Seki, Y., Iwaki, T., Hashioka, S., Kanba, 
S., 2008. Inhibitory effects of aripiprazole on interferon-γ-induced microglial activation via intracellular 
Ca2+ regulation in vitro. Journal of Neurochemistry 106(2), 815-825. 
Kenk, M., Selvanathan, T., Rao, N., Suridjan, I., Rusjan, P., Remington, G., Meyer, J.H., Wilson, A.A., 
Houle, S., Mizrahi, R., 2015. Imaging neuroinflammation in gray and white matter in schizophrenia: an 
in-vivo PET study with [18F]-FEPPA. Schizophr Bull 41(1), 85-93. 
Kirkpatrick, B., Miller, B.J., 2013. Inflammation and schizophrenia. Schizophr Bull 39(6), 1174-1179. 
Kreisl, W.C., Lyoo, C.H., McGwier, M., Snow, J., Jenko, K.J., Kimura, N., Corona, W., Morse, C.L., 
Zoghbi, S.S., Pike, V.W., McMahon, F.J., Turner, R.S., Innis, R.B., Team, B.C.P.R.P., 2013. In vivo 
radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 136(Pt 
7), 2228-2238. 
Kreutzberg, G.W., 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 
19(8), 312-318. 
24 
 
Lartey, F.M., Ahn, G.O., Shen, B., Cord, K.T., Smith, T., Chua, J.Y., Rosenblum, S., Liu, H., James, 
M.L., Chernikova, S., Lee, S.W., Pisani, L.J., Tirouvanziam, R., Chen, J.W., Palmer, T.D., Chin, F.T., 
Guzman, R., Graves, E.E., Loo, B.W., 2014. PET imaging of stroke-induced neuroinflammation in 
mice using [18F]PBR06. Mol Imaging Biol 16(1), 109-117. 
Laskaris, L.E., Di Biase, M.A., Everall, I., Chana, G., Christopoulos, A., Skafidas, E., Cropley, V.L., 
Pantelis, C., 2016. Microglial activation and progressive brain changes in schizophrenia. Br J 
Pharmacol 173(4), 666-680. 
Lockhart, A., Davis, B., Matthews, J.C., Rahmoune, H., Hong, G., Gee, A., Earnshaw, D., Brown, J., 
2003. The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute 
phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory 
marker. Nucl Med Biol 30(2), 199-206. 
Loggia, M.L., Chonde, D.B., Akeju, O., Arabasz, G., Catana, C., Edwards, R.R., Hill, E., Hsu, S., 
Izquierdo-Garcia, D., Ji, R.R., Riley, M., Wasan, A.D., Zürcher, N.R., Albrecht, D.S., Vangel, M.G., 
Rosen, B.R., Napadow, V., Hooker, J.M., 2015. Evidence for brain glial activation in chronic pain 
patients. Brain 138(Pt 3), 604-615. 
Lyoo, C.H., Ikawa, M., Liow, J.-S., Zoghbi, S.S., Morse, C.L., Pike, V.W., Fujita, M., Innis, R.B., Kreisl, 
W.C., 2015. Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect 
Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. Journal of 
Nuclear Medicine 56(5), 701-706. 
Mattner, F., Staykova, M., Berghofer, P., Wong, H.J., Fordham, S., Callaghan, P., Jackson, T., Pham, 
T., Gregoire, M.C., Zahra, D., Rahardjo, G., Linares, D., Katsifis, A., 2013. Central nervous system 
expression and PET imaging of the translocator protein in relapsing-remitting experimental 
autoimmune encephalomyelitis. J Nucl Med 54(2), 291-298. 
Meisenzahl EM, R.D., Kirner A 2001. Association of an interleukin-1β genetic polymorphism with 
altered brain structure in patients with schizophrenia. . Am. J. Psychiatry 158: 1316–1319. 
Mondelli, V., Howes, O., 2014. Inflammation: its role in schizophrenia and the potential anti-
inflammatory effects of antipsychotics. Psychopharmacology (Berl) 231(2), 317-318. 
Montgomery, A.J., Thielemans, K., Mehta, M.A., Turkheimer, F., Mustafovic, S., Grasby, P.M., 2006. 
Correction of Head Movement on PET Studies: Comparison of Methods. Journal of Nuclear Medicine 
47(12), 1936-1944. 
Myers, R., Manjil, L.G., Frackowiak, R.S., Cremer, J.E., 1991. [3H]PK 11195 and the localisation of 
secondary thalamic lesions following focal ischaemia in rat motor cortex. Neurosci Lett 133(1), 20-24. 
Narendran, R., Frankle, W.G., 2016. Comment on Analyses and Conclusions of "Microglial Activity in 
People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging 
Study". Am J Psychiatry 173(5), 536-537. 
Nichols, T., Hayasaka, S., 2003. Controlling the familywise error rate in functional neuroimaging: a 
comparative review. Stat Methods Med Res 12(5), 419-446. 
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., Torizuka, T., 2005. 
Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57(2), 168-
175. 
Owen, D.R., Guo, Q., Kalk, N.J., Colasanti, A., Kalogiannopoulou, D., Dimber, R., Lewis, Y.L., Libri, V., 
Barletta, J., Ramada-Magalhaes, J., Kamalakaran, A., Nutt, D.J., Passchier, J., Matthews, P.M., Gunn, 
R.N., Rabiner, E.A., 2014. Determination of [(11)C]PBR28 binding potential in vivo: a first human 
TSPO blocking study. J Cereb Blood Flow Metab 34(6), 989-994. 
Owen, D.R., Yeo, A.J., Gunn, R.N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D.J., 
Bennacef, I., Parker, C.A., StJean, P.L., Cardon, L.R., Mooser, V.E., Matthews, P.M., Rabiner, E.A., 
Rubio, J.P., 2011. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in 
binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32(1), 1-5. 
Pantelis, C., Velakoulis, D., McGorry, P.D., Wood, S.J., Suckling, J., Phillips, L.J., Yung, A.R., 
Bullmore, E.T., Brewer, W., Soulsby, B., Desmond, P., McGuire, P.K., 2003. Neuroanatomical 
abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. 
Lancet 361(9354), 281-288. 
Paolicelli, R.C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, 
T.A., Guiducci, E., Dumas, L., Ragozzino, D., Gross, C.T., 2011. Synaptic pruning by microglia is 
necessary for normal brain development. Science 333(6048), 1456-1458. 
25 
 
Pappata, S., Levasseur, M., Gunn, R.N., Myers, R., Crouzel, C., Syrota, A., Jones, T., Kreutzberg, 
G.W., Banati, R.B., 2000. Thalamic microglial activation in ischemic stroke detected in vivo by PET 
and [11C]PK1195. Neurology 55(7), 1052-1054. 
Qian, J., Hastie, T., Friedman, J., Tibshirani, R., Simon, N., 2013. Glmnet for Matlab. 
Radewicz, K., Garey LJ, Gentleman SM, Reynolds R 2000. Increase in HLA-DR immunoreactive 
microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59:, 
137–150. 
Radlinska, B.A., Ghinani, S.A., Lyon, P., Jolly, D., Soucy, J.P., Minuk, J., Schirrmacher, R., Thiel, A., 
2009. Multimodal microglia imaging of fiber tracts in acute subcortical stroke. Ann Neurol 66(6), 825-
832. 
Ramlackhansingh, A.F., Brooks, D.J., Greenwood, R.J., Bose, S.K., Turkheimer, F.E., Kinnunen, K.M., 
Gentleman, S., Heckemann, R.A., Gunanayagam, K., Gelosa, G., Sharp, D.J., 2011. Inflammation 
after trauma: microglial activation and traumatic brain injury. Ann Neurol 70(3), 374-383. 
Rao, V.L.R., Butterworth, R.F., 1997. Characterization of binding sites for the ω3 receptor ligands 
[3H]PK11195 and [3H]RO5-4864 in human brain. European Journal of Pharmacology 340(1), 89-99. 
Rissanen, E., Tuisku, J., Rokka, J., Paavilainen, T., Parkkola, R., Rinne, J.O., Airas, L., 2014. In Vivo 
Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging 
and the Radioligand ¹¹C-PK11195. J Nucl Med 55(6), 939-944. 
Rizzo, G., Veronese, M., Tonietto, M., Zanotti-Fregonara, P., Turkheimer, F.E., Bertoldo, A., 2014. 
Kinetic modeling without accounting for the vascular component impairs the quantification of 
[lsqb]11C[rsqb]PBR28 brain PET data. J Cereb Blood Flow Metab. 
Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T.C., Fan, J., Akula, N., Groyer, G., Adams, 
D., Schumacher, M., 2010. Translocator protein (18 kDa) (TSPO) as a therapeutic target for 
neurological and psychiatric disorders. Nat Rev Drug Discov 9(12), 971-988. 
Schuitemaker, A., van der Doef, T.F., Boellaard, R., van der Flier, W.M., Yaqub, M., Windhorst, A.D., 
Barkhof, F., Jonker, C., Kloet, R.W., Lammertsma, A.A., Scheltens, P., van Berckel, B.N., 2012a. 
Microglial activation in healthy aging. Neurobiol Aging 33(6), 1067-1072. 
Schuitemaker, A., van der Doef, T.F., Boellaard, R., van der Flier, W.M., Yaqub, M., Windhorst, A.D., 
Barkhof, F., Jonker, C., Kloet, R.W., Lammertsma, A.A., Scheltens, P., van Berckel, B.N.M., 2012b. 
Microglial activation in healthy aging. Neurobiology of Aging 33(6), 1067-1072. 
Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, 
J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Daly, M.J., Carroll, M.C., 
Stevens, B., McCarroll, S.A., Consortium, S.W.G.o.t.P.G., 2016. Schizophrenia risk from complex 
variation of complement component 4. Nature 530(7589), 177-183. 
Shapiro, S., Wilk, M. B., 1965. An analysis of variance test for normality (complete samples). 
Biometrika 52(3-4), 591-611. 
Smith, S.E., Li, J., Garbett, K., Mirnics, K., Patterson, P.H., 2007. Maternal immune activation alters 
fetal brain development through interleukin-6. J Neurosci 27(40), 10695-10702. 
Spitzer, R.L., Williams, J.W., Gibbon, M., First, M.B., 1992. The structured clinical interview for dsm-iii-
r (scid): I: history, rationale, and description. Archives of General Psychiatry 49(8), 624-629. 
Sun, D., Phillips, L., Velakoulis, D., Yung, A., McGorry, P.D., Wood, S.J., van Erp, T.G., Thompson, 
P.M., Toga, A.W., Cannon, T.D., Pantelis, C., 2009. Progressive brain structural changes mapped as 
psychosis develops in 'at risk' individuals. Schizophr Res 108(1-3), 85-92. 
Tonietto, M., Rizzo, G., Veronese, M., Bertoldo, A., 2015. Modelling arterial input functions in positron 
emission tomography dynamic studies. Conf Proc IEEE Eng Med Biol Soc 2015, 2247-2250. 
Tonietto, M., Rizzo, G., Veronese, M., Fujita, M., Zoghbi, S.S., Zanotti-Fregonara, P., Bertoldo, A., 
2016. Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling 
approaches. J Cereb Blood Flow Metab 36(2), 326-339. 
Trépanier, M.O., Hopperton, K.E., Mizrahi, R., Mechawar, N., Bazinet, R.P., 2016. Postmortem 
evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry 21(8), 1009-
1026. 
Turkheimer, Federico E., Rizzo, G., Bloomfield, Peter S., Howes, O., Zanotti-Fregonara, P., Bertoldo, 
A., Veronese, M., 2015a. The methodology of TSPO imaging with positron emission tomography. 
Biochemical Society Transactions 43(4), 586-592. 
26 
 
Turkheimer, F.E., Rizzo, G., Bloomfield, P.S., Howes, O., Zanotti-Fregonara, P., Bertoldo, A., 
Veronese, M., 2015b. The methodology of TSPO imaging with positron emission tomography. 
Biochem Soc Trans 43(4), 586-592. 
Tziortzi, A.C., Searle, G.E., Tzimopoulou, S., Salinas, C., Beaver, J.D., Jenkinson, M., Laruelle, M., 
Rabiner, E.A., Gunn, R.N., 2011. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: 
Dissection of D3 signal and anatomy. NeuroImage 54(1), 264-277. 
van Berckel, B.N., Bossong, M.G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, 
G., Windhorst, A.D., Cahn, W., Lammertsma, A.A., Kahn, R.S., 2008. Microglia Activation in Recent-
Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study. 
Biological Psychiatry 64(9), 820-822. 
van der Doef, T.F., de Witte, L.D., Sutterland, A.L., Jobse, E., Yaqub, M., Boellaard, R., de Haan, L., 
Eriksson, J., Lammertsma, A.A., Kahn, R.S., van Berckel, B.N., 2016. In vivo (R)-[(11)C]PK11195 PET 
imaging of 18kDa translocator protein in recent onset psychosis. NPJ Schizophr 2, 16031. 
Van Haren, N.E., Cahn, W., Hulshoff Pol, H.E., Kahn, R.S., 2013. Confounders of excessive brain 
volume loss in schizophrenia. Neurosci Biobehav Rev 37(10 Pt 1), 2418-2423. 
van Haren, N.E., Hulshoff Pol, H.E., Schnack, H.G., Cahn, W., Brans, R., Carati, I., Rais, M., Kahn, 
R.S., 2008. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of 
maturational abnormalities in early adulthood. Biol Psychiatry 63(1), 106-113. 
van Kesteren, C.F., Gremmels, H., de Witte, L.D., Hol, E.M., Van Gool, A.R., Falkai, P.G., Kahn, R.S., 
Sommer, I.E., 2017. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on 
postmortem brain studies. Transl Psychiatry 7(3), e1075. 
Veronese, M., Reis Marques, T., Bloomfield, P.S., Rizzo, G., Singh, N., Jones, D., Agushi, E., Mosses, 
D., Bertoldo, A., Howes, O., Roncaroli, F., Turkheimer, F.E., 2017. Kinetic modelling of [(11)C]PBR28 
for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using 
XBD173 and tissue analysis. J Cereb Blood Flow Metab, 271678X17712388. 
Volk, D.W., Chitrapu, A., Edelson, J.R., Roman, K.M., Moroco, A.E., Lewis, D.A., 2015. Molecular 
mechanisms and timing of cortical immune activation in schizophrenia. Am J Psychiatry 172(11), 
1112-1121. 
Walterfang, M., McGuire, P.K., Yung, A.R., Phillips, L.J., Velakoulis, D., Wood, S.J., Suckling, J., 
Bullmore, E.T., Brewer, W., Soulsby, B., Desmond, P., McGorry, P.D., Pantelis, C., 2008. White matter 
volume changes in people who develop psychosis. Br J Psychiatry 193(3), 210-215. 
Witthaus, H., Brüne, M., Kaufmann, C., Bohner, G., Ozgürdal, S., Gudlowski, Y., Heinz, A., Klingebiel, 
R., Juckel, G., 2008. White matter abnormalities in subjects at ultra high-risk for schizophrenia and 
first-episode schizophrenic patients. Schizophr Res 102(1-3), 141-149. 
Yung, A.R., Pan Yuen, H., McGorry, P.D., Phillips, L.J., Kelly, D., Dell'olio, M., Francey, S.M., 
Cosgrave, E.M., Killackey, E., Stanford, C., Godfrey, K., Buckby, J., 2005. Mapping the Onset of 
Psychosis: The Comprehensive Assessment of At-Risk Mental States. Australian and New Zealand 
Journal of Psychiatry 39(11-12), 964-971. 
Zhang  , Y., Catts  , V.S., Sheedy  , D., McCrossin  , T., Kril  , J.J., Weickert  , C.S., 2016. Cortical grey 
matter volume reduction in people with schizophrenia is associated with neuro-inflammation. 
Translational Psychiatry(6), e982. 
Zhu F, Z.Y., Ding Y-q, Liu Y, Zhang X, et al. , 2014. Minocycline and Risperidone Prevent Microglia 
Activation and Rescue Behavioral Deficits Induced by Neonatal Intrahippocampal Injection of 
Lipopolysaccharide in Rats. PLoS ONE 9(4): e93966. 
Ziermans, T.B., Schothorst, P.F., Schnack, H.G., Koolschijn, P.C., Kahn, R.S., van Engeland, H., 
Durston, S., 2012. Progressive structural brain changes during development of psychosis. Schizophr 
Bull 38(3), 519-530. 
Zou, H., Hastie, T., Regularization and variable selection via the elastic net. 
Zürcher, N.R., Loggia, M.L., Lawson, R., Chonde, D.B., Izquierdo-Garcia, D., Yasek, J.E., Akeju, O., 
Catana, C., Rosen, B.R., Cudkowicz, M.E., Hooker, J.M., Atassi, N., 2015. Increased in vivo glial 
activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage 
Clin 7, 409-414. 
 
 
27 
 
TABLES 
 
Table 1: Brain morphometric volume differences (cm3) 
 
 
SCZ 
Mean 
(SD) 
N=14 
CTRL 
Mean 
(SD) 
N=14 
P value 
FDR 
0.05 
UHR 
Mean 
(SD) 
N=14 
CTRL 
Mean 
(SD) 
N=14 
P value 
FDR 
0.05 
Total Cortical GM 448.83 (39.19) 
499.57 
(59.21) 0.02* 
503.06 
(57.94) 
 
524.46 
(45.27) 0.30 
Frontal Cortical GM 129.44 (11.84) 
138.62 
(18.37) 0.15 
143.75 
(16.06) 
148.67 
(13.18) 0.40 
Temporal Cortical GM 101.32 (9.10) 
115.97 
(13.94) 0.01* 
116.068 
(15.138) 
121.59 
(12.80) 0.32 
Brain regions significant at FDR <0.05 in whole brain volume analysis 
Left cuneus GM 2.80 (0.37) 
3.51 
(0.45) 0.0003 
3.16 
(0.40) 
3.58 
(0.31) NS 
Right superior 
parietal cortex GM 
12.22 
(1.28) 
13.97 
(1.01) 0.001 
13.81 
(.40) 
14.36 
(1.41) NS 
Right transverse temporal cortex 
GM 
0.82 
(0.16) 
1.07 
(0.16)) 0.001 
 
1.016.9 
(0.16) 
 
 
1.12 
(.21) 
 
NS 
GM=gray matter; FDR=false discovery rate; SCZ=schizophrenia; CTRL=control 
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FIGURES 
 
Figure 1. Negative correlation between normalized volume of right superior parietal 
cortex and [11C]PBR28 gray matter DVR (a) and the distribution of r and –logp for the 
1000 regressions (b).  
 
 
 
Figure 2. Negative correlation between normalized volume of left temporal pole and 
temporal [11C]PBR28 gray matter DVR (a) and the distribution of r and –logp for the 
1000 regressions (b). 
 
(a) (b)
Controls	(CTRL);	Schizophrenia	(SCZ);	gray	matter	(GM);	Distribution	volume	ratio	(DVR).
Temporal	GM	DVR	
(a)			 (b)
Controls	(CTRL);	Schizophrenia	(SCZ);	gray	matter	(GM);	Distribution	volume	ratio	(DVR).
